Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05507827 · ClinicalTrials.gov registry record · Phase 1
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
A Phase 1 study of Lymphoid Leukemia, sponsored by Stanford University.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05507827: Active Phase 1 study of Lymphoid Leukemia, sponsored by Stanford University.
NCT05507827 is a Phase 1 study of Lymphoid Leukemia that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 22 participants, below the 182-participant average among 3 other Lymphoid Leukemia trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05507827, a Phase 1 study of Lymphoid Leukemia, is active but no longer recruiting, sponsored by Stanford University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.
Primary Outcome
Will be measured by the ability to manufacture donor CD19/CD22-CAR T cells that meet established release specifications
Conditions Studied
Interventions
- DRUG Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)
- DRUG Treg CD34+HSPC (Orca-T)
Study Locations (1)
California
- Stanford Cancer Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-08-18 |
| Est. Completion | 2026-05 |
| Phase | Phase 1 |
What the registry record for NCT05507827 still lists
NCT05507827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 182-participant average among 3 other Lymphoid Leukemia trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Lymphoid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR) is the first listed.
NCT05507827 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05507827 about?
NCT05507827 is a clinical study titled "Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL". To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD ...
What is the current status of trial NCT05507827?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2022-08-18. Estimated completion is 2026-05.
What conditions does trial NCT05507827 study?
This clinical trial studies the following conditions: Lymphoid Leukemia.
What interventions are being tested in trial NCT05507827?
The interventions under investigation include: Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR) (DRUG), Treg CD34+HSPC (Orca-T) (DRUG).
Who is sponsoring clinical trial NCT05507827?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05507827 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI